New combo aims to shrink penile cancer before surgery
NCT ID NCT06353906
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether giving pembrolizumab (Keytruda) plus chemotherapy (carboplatin and paclitaxel) before surgery can completely eliminate advanced penile cancer in the penis and lymph nodes. About 27 men with resectable, node-positive penile cancer will receive the combination, then undergo surgery. The main goal is to see how many achieve a complete response (no cancer found in the removed tissue).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (Keytruda) plus carboplatin and paclitaxel
- What this could lead to
- If successful, this combination could become a new standard treatment to shrink advanced penile cancer before surgery, potentially improving outcomes.
- What could go wrong
- This is a small, early-phase trial with only 27 participants, so results may not apply broadly. Chemo-immunotherapy can cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PENILE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NKI-AVL
RECRUITINGAmsterdam, North Holland, 1066CX, Netherlands
-
UZ Leuven
RECRUITINGLeuven, 3000, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
- Can AI outthink cancer experts? a landmark trial pits five AIs against tumor boards
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
- Penis transplants could restore form and function for wounded warriors